gene therapyBayer’s Ask Bio unit starts Phase II...Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure. more ➔
LabGerman companies to revolutionise lab plas...German Green Elephant Biotech has launched the world’s first plant-based 96-well microtitre plate on the market. more ➔
financingAMPLY Discovery Ltd bags £1.4m funding to...Belfast-based techbio company AMPLY Discovery Ltd announced today will make use of a £1.4m in grant funding to advance its AI-based drug discovery platform. more ➔
financingCambridge university spin-out HutanBio Ltd...British-Malasian marine algae biofuel start-up HutanBio has secured an £2.25m seed investment to produce carbon negative biodiesel in brackish water. more ➔
agri-biotechEU parliament backs deregulation of New Ge...After two "Yes"-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding. … more ➔
partnershipJazz Pharmaceuticals licences KRAS blocker...Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules. more ➔
financingSpanish plant-based protein producer Heür...Spanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution. more ➔
CDMOBiovian and 3P Biopharmaceuticals join for...Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN. more ➔
RNALonza and Oxford Nanopore collaborate to a...To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA … more ➔
CRO£26m for Cystic Fibrosis Drug Trial Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors. more ➔
